Clinical trials · Riverside–San Bernardino, CA
Metastatic Cancer clinical trials in Riverside–San Bernardino
We’re tracking 278 recruiting metastatic cancer studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT07702032RecruitingPhase 3
Study of petosemtamab plus chemo for left-sided colorectal cancer
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
Los Angeles, CaliforniaAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Los Angeles, CaliforniaAges 18 years+ - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Los Angeles, CaliforniaAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Los Angeles, CaliforniaAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Los Angeles, CaliforniaAges 18 years+ - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Los Angeles, CaliforniaAges 18–130 - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Los Angeles, CaliforniaAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT05394103RecruitingPhase 1/Phase 2
Testing a targeted pill for hard-to-treat solid tumors
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Los Angeles, CaliforniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 19 years+ - NCT06615752RecruitingPhase 1/Phase 2
Green tea and quercetin with chemo for prostate cancer
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT04907643Recruiting
Virtual reality program to reduce stomach-cancer pain
This trial tests whether virtual reality (VR) can improve pain and other day-to-day symptoms in people with certain gastrointestinal cancers. You’d use VR for pain relief while researchers measure how you’re feeling.
Los Angeles, CaliforniaAges 18–99
Hear when a new Metastatic Cancer trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Cancer trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting metastatic cancer studies listed above.
- USC Norris Comprehensive Cancer Center · 5 studies
- Cedars-Sinai Medical Center · 4 studies
- UCLA Jonsson Comprehensive Cancer Center · 3 studies
- Research Site · 2 studies
- University of California, Los Angeles · 2 studies
- University of Southern California · 2 studies
- VA Greater Los Angeles Healthcare System · 2 studies
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic cancer studies in California.
Common questions
- Are there metastatic cancer clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 278 recruiting metastatic cancer studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.